VD11-4-2

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564972

CAS#: NONE

Description: VD11-4-2 is a potent and selective CA IX inhibitor.


Price and Availability

Size
Price

Size
Price

Size
Price

VD11-4-2 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 564972
Name: VD11-4-2
CAS#: NONE
Chemical Formula: C16H23F3N2O5S2
Exact Mass: 444.1
Molecular Weight: 444.48
Elemental Analysis: C, 43.24; H, 5.22; F, 12.82; N, 6.30; O, 18.00; S, 14.43


Synonym: VD1142; VD11 4 2; VD11-4-2

IUPAC/Chemical Name: 3-(Cyclooctylamino)-2,5,6-trifluoro-4-((2-hydroxyethyl)sulfonyl)benzenesulfonamide

InChi Key: HFJJAVOBUVMVFQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H23F3N2O5S2/c17-11-12(18)16(27(23,24)9-8-22)14(13(19)15(11)28(20,25)26)21-10-6-4-2-1-3-5-7-10/h10,21-22H,1-9H2,(H2,20,25,26)

SMILES Code: O=S(C1=C(F)C(F)=C(S(=O)(CCO)=O)C(NC2CCCCCCC2)=C1F)(N)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934990300


References

1: Janoniene A, Liu Z, Baranauskiene L, Mäkilä E, Ma M, Salonen J, Hirvonen J, Zhang H, Petrikaite V, Santos HA. A Versatile Carbonic Anhydrase IX Targeting Ligand-Functionalized Porous Silicon Nanoplatform for Dual Hypoxia Cancer Therapy and Imaging. ACS Appl Mater Interfaces. 2017 Apr 26;9(16):13976-13987. doi: 10.1021/acsami.7b04038. Epub 2017 Apr 11. PubMed PMID: 28383881.

2: Kazokaitė J, Aspatwar A, Kairys V, Parkkila S, Matulis D. Fluorinated benzenesulfonamide anticancer inhibitors of carbonic anhydrase IX exhibit lower toxic effects on zebrafish embryonic development than ethoxzolamide. Drug Chem Toxicol. 2017 Jul;40(3):309-319. doi: 10.1080/01480545.2016.1223095. Epub 2016 Sep 6. PubMed PMID: 27600313.

3: Kazokaitė J, Ames S, Becker HM, Deitmer JW, Matulis D. Selective inhibition of human carbonic anhydrase IX in Xenopus oocytes and MDA-MB-231 breast cancer cells. J Enzyme Inhib Med Chem. 2016;31(sup4):38-44. Epub 2016 Aug 24. PubMed PMID: 27557419.